← Back to All Filings

Turn Therapeutics CFO Acquires Additional TTRX Shares in Small Purchase

Low SignificanceNovember 17, 2025 at 9:31:57 PM EST

Turn Therapeutics Inc.

$TTRX4CIK: 0002023016

Subscribe to track TTRX

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Turn Therapeutics CFO Acquires TTRX Shares

Company: Turn Therapeutics Inc. (TTRX) Form: 4 | Filed: 2025-11-17 Significance: Low

Insider: Chaudhary Zuraiz Title: Interim CFO, VP of Finance & CAO | Relationship: Officer

Transaction: • Type: Buy • Shares: 2,500 • Price: $3.62 (avg) • Value: $9,050 • Owned After: 7,550

Key Insight: A key financial executive made a small open-market purchase, a positive signal, but the transaction's value is negligible relative to the company's market cap.

Market Context: The purchase represents less than 0.01% of the company's $110 million market capitalization, indicating a minor addition to the insider's position.

Comprehensive Analysis

SEC Filing Analysis: Turn Therapeutics Inc. (TTRX)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The Interim Chief Financial Officer of Turn Therapeutics made a small open-market purchase of common stock valued at approximately $9,050.
  • Market Impact: Neutral. The transaction size is too small to be considered market-moving.

Company Information

FieldValue
CompanyTurn Therapeutics Inc.
Ticker SymbolTTRX
CIK0002023016
IndustryPharmaceutical Preparations

Insider Information

FieldValue
NameChaudhary Zuraiz
CIK0002086494
Title/PositionInterim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer.
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-17
Transaction CodeP (Open Market Purchase)
Security TypeCommon Stock
Shares Involved2,500
Price Per Share$3.62
Total Value$9,050
Shares Owned After7,550
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$9,050
% of Market Cap0.0082%
Shares Transacted2,500
% of Shares OutstandingNot Available
Post-Transaction Ownership7,550 shares
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: The transaction value of $9,050 is negligible when compared to Turn Therapeutics' market capitalization of $110 million. It represents a very small fraction of the company's total value.
  • Ownership Concentration: Without data on shares outstanding, the insider's total ownership percentage cannot be calculated. However, the purchase itself is minor.
  • Transaction Significance: The purchase is considered to have low significance. While insider buys are generally positive indicators, the extremely small size of this transaction relative to the company's market cap diminishes its signaling power.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: An open-market purchase by a CFO is a positive sign of confidence. However, the total value of $9,050 is insignificant for a company with a $110 million market cap, making any market reaction unlikely.

Volume & Sentiment

  • Expected Volume Impact: Minimal. The transaction is too small to impact trading volume.
  • Sentiment Indicator: Neutral. The positive nature of the buy is offset by its immaterial size.

Additional Context

Transaction Notes

  • The reported price of $3.62 is a weighted average. The shares were purchased in multiple transactions at prices ranging from $3.50 to $3.69.
Topics:#SECFiling#InsiderTrading#TTRX#Form4#InsiderBuy#TurnTherapeutics#StockMarket#Investing#Finance

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.